

Nirmatrelvir–ritonavir not effective for reducing most post-COVID-19 conditions: Study

October 30 2023



Credit: Pixabay/CC0 Public Domain

A trial emulation study of veterans with COVID-19 has found that the use of the antiviral nirmatrelvir–ritonavir was not effective for reducing

the risk for many post-COVID-19 conditions, including cardiac, pulmonary, renal, gastrointestinal, neurologic, mental health, musculoskeletal, or endocrine symptoms. Nirmatrelvir–ritonavir was associated only with a reduced risk for combined thromboembolic events. [The study](#) is published in *Annals of Internal Medicine*.

A study from the Centers for Disease Control and Prevention suggested that 1 in 5 COVID-19 survivors aged 18 to 64 years and 1 in 4 survivors aged 65 years or older experienced an incident condition that was potentially attributable to previous COVID-19 infection. Nirmatrelvir–ritonavir is often recommended to nonhospitalized persons with symptomatic COVID-19 who are at high risk for severe COVID-19. However, its ability to reduce risk for post-COVID-19 conditions is unknown.

Researchers from the Veterans Administration Puget Sound Healthcare System evaluated 9,593 nonhospitalized patients treated with nirmatrelvir-ritonavir and their matched untreated cohorts for 31 PCCs to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir–ritonavir in preventing PCCs.

No differences were observed between the two groups except for a lower combined risk for venous thromboembolism and [pulmonary embolism](#). According to the authors, their results suggest that considerations about PCCs may not be an important factor in COVID-19 treatment decisions.

More information: *Annals of Internal Medicine* (2023).
<https://www.acpjournals.org/doi/10.7326/M23-1394>

Provided by American College of Physicians

Citation: Nirmatrelvir–ritonavir not effective for reducing most post-COVID-19 conditions: Study (2023, October 30) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-10-nirmatrelvirritonavir-effective-post-covid-conditions.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.